Exhaled nitric oxide is related to bronchial eosinophilia and airway hyperresponsiveness to bradykinin in allergen-induced asthma exacerbation. by Ricciardolo, Flm et al.
         
 
1 
 
 
 
 
 
 
This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):175-82. 
 
 
The definitive version is available at: 
La versione definitiva è disponibile alla URL: 
http://www.biolifesas.org/rosso.htm 
 
 
 
 
 
 
 
 
         
 
2 
 
 
EXHALED NITRIC OXIDE IS RELATED TO BRONCHIAL EOSINOPHILIA 
AND AIRWAY HYPERRESPONSIVENESS TO BRADYKININ IN ALLERGEN-
INDUCED ASTHMA EXACERBATION 
F.L.M. RICCIARDOLO MD, PHD
1
, A. DI STEFANO, PHD
2
, M. SILVESTRI, PHD
3
, 
A.M. VAN SCHADEWIJK, MD
4
, M. MALERBA, MD
5
, P.S. HIEMSTRA, PHD
4
, P.J. 
STERK, MD
6
.  
 
1
Division of Respiratory Disease, Department of Clinical and Biological Sciences-
University of Torino, Orbassano (Torino), Italy, 
2
Division of Pneumology, S. Maugeri 
Foundation, Veruno (Novara), Italy, 
3
Pediatric Pulmonology and Allergy Unit, G. 
Gaslini Institute, Genoa, Italy, 
4
Department of Pulmonology, Leiden University Medical 
Centre, The Netherlands; 
5
Department of Internal Medicine, University of Brescia, 
Brescia, Italy; 
6
Department Respiratory Medicine, Academic Medical Centre, 
University of Amsterdam, Amsterdam. 
 
Author for correspondence and requests for reprints: Dr. Fabio L.M. Ricciardolo, 
Division of Respiratory Disease, Department of Clinical and Biological Sciences-
University of Torino, A.O.U. San Luigi Gonzaga, Regione Gonzole, 10, 10043 
Orbassano (Torino), Italy 
 
Key words: exhaled nitric oxide; allergen; asthma; eosinophils; airway 
hyperresponsiveness 
 
The authors have no declared conflict of interests 
         
 
3 
 
 
Summary   
Exhaled nitric oxide (FeNO) has been associated with bronchial eosinophilia and with 
airway hyperresponsiveness (AHR) in mild stable asthma. We previously demonstrated 
in a large project that allergen exposure is able to raise FeNO and to worsen AHR to 
bradykinin. We postulated that allergen-induced increase in FeNO could be related to 
heightened mucosal eosinophils and AHR to bradykinin in atopic asthma. We 
performed a new immunohistochemical analysis on bronchial biopsies specimens, 
previously obtained from the same large project, in order to assess the number of 
mucosal eosinophils (EG-2
+
 cell) and other inflammatory cells at 48 hours after diluent 
and allergen exposures. Inflammatory cell counts were related to FeNO and AHR to BK 
(expressed as logPD20 bradykinin). In 10 atopic mild asthmatics, we found that the 
numbers of EG-2
+
 and CD4
+
 cells in bronchial submucosa were significantly increased 
after allergen compared to the respective counts after diluent (p < 0.01). EG-2
+
 cells in 
the bronchial submucosa were negatively correlated with logPD20 bradykinin only after 
allergen challenge (rho = -0.709, p = 0.027). We also found a positive strong correlation 
between EG-2
+
 cells and FeNO values in atopic asthmatics at 48 hours after both diluent 
(rho = 0.746, p = 0.017) and allergen (rho = 0.644, p = 0.049) challenge. FeNO values 
negatively correlated with responsiveness to bradykinin only after allergen challenge 
(rho = -0.675, p = 0.039). This study indicates that after allergen exposure heightened 
level of exhaled NO may reflect augmented airway eosinophilic inflammation and 
airway responsiveness to bradykinin indicating loss of asthma control. Michi, ora è più 
chiara? 
Word count in abstract: 254 
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INTRODUCTION 
A plethora of studies by using bronchial mucosal biopsies demonstrated that bronchial 
asthma is a chronic inflammatory disease of the airways characterized by the presence 
of an array of activated inflammatory cells and mediators. Biopsy specimens from 
proximal bronchi obtained through a fiberoptic bronchoscope are the most direct 
method of measuring airway inflammation and are considered the “gold standard” for 
assessment of airway inflammation in asthma against which other methods should be 
compared (1). Different noninvasive methods have been proposed for monitoring 
inflammation in asthma, and in particular exhaled nitric oxide [FeNO] has been 
indicated as surrogate marker of airway inflammation (2). 
FeNO is elevated in patients with atopic asthma (2) and is related, before and after 
steroid treatment, to sputum eosinophilia (3, 4) and bronchoalveolar lavage [BAL] 
eosinophil counts (5) in adult patients, and to airway eosinophilic inflammation in BAL 
(6) and biopsies of children patients (7). In addition, in sensitized asthmatics with late 
asthmatic response [LAR] after allergen exposure FeNO is elevated (8) suggesting that 
FeNO may reflect allergic inflammation in exacerbated asthmatic airways. 
Airway hyperresponsiveness [AHR] to nonspecific bronchoconstrictor stimuli is a 
key feature of asthma and is associated with the underlying inflammatory process of the 
disease (9). AHR is regarded as a marker of disease severity and control (9). A previous 
study showed a significant relationship between AHR to bradykinin, but not to 
methacholine, and eosinophilic inflammation in a wide range of subjects with mild-to-
moderate asthma treated and not treated with corticosteroids (10), proposing AHR to 
bradykinin as a clinical marker of assessing severity of asthma.  
We previously demonstrated in a larger asthma clinical trial that allergen exposure is 
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able to raise FeNO during LAR (8) and to worsen AHR to bradykinin (11). We 
postulated that allergen-induced increase in FeNO could be related to heightened 
mucosal eosinophils and AHR to bradykinin in atopic asthma. For this purpose we 
performed new immunohistochemical analysis on bronchial biopsies specimens, 
obtained from the same large project (11) in order to assess the number of mucosal 
eosinophils and other inflammatory cells at 48 hours after diluent and allergen (house 
dust mite) exposures. Furthermore, inflammatory cell counts were related to the 
previously published data (FeNO and AHR to bradykinin). 
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MATERIAL AND METHODS 
Subjects 
Ten non-smoking house dust mite [HDM]-atopic individuals with mild intermittent 
asthma participated in the study which was part of a larger project (11). The 
characteristics of the participants have been previously published (11). Briefly, all 
participants met the criteria of mild intermittent asthma and were symptom-free at the 
time of the study; none of them were on regular medications. Their values of baseline 
FEV1 were >70% of predicted and were hyperresponsive to inhaled histamine 
(provocative concentration producing a 20% fall from baseline FEV1 [PC20] < 8.0 
mg/mL). None of the participants had a history of relevant allergen exposure or 
respiratory tract infection in the 6 weeks before and during the study. Inhaled short-
acting β2-agonists and beverages containing xanthines were withheld for at least 12 
hours before testing. The subjects had a documented early asthmatic response [EAR] 
and LAR to inhaled HDM extract in the screening period. The study was approved by 
the Medical Ethics Committee of the Leiden University Medical Centre, and all the 
patients gave written informed consent. 
 
Study design  
The study had a randomized, placebo-controlled and cross-over design. FeNO 
measurements, bradykinin challenges (to measure AHR to bradykinin) and 
bronchoscopy were performed in each patient 2 days after either allergen or diluent 
exposure (11). Each exposure was separated by a wash-out interval of at least 2 weeks. 
Exhaled NO measurements were performed before and after each challenge at 48 hours. 
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We considered the bronchial biopsies carried out at 2 days after diluent challenge as 
baseline (11).  
 
Bradykinin and allergen challenge, FeNO and bronchoscopy 
Bradykinin challenge (expressed as logPD20 bradykinin), diluent/allergen challenge, 
FeNO measurements (ppb values) and fiberoptic bronchoscopy were performed as 
previously described (8, 11).  
 
Immunohistochemistry   
Three biopsy samples per subject were formalin-fixed and paraffin embedded. Four 
micrometer [m] thick sections were used for immunohistochemistry. Sections were 
incubated overnight with mouse primary monoclonal antibodies directed against EG-2 
(Pharmacia - Netherlands), CD4 (Novocastra – UK), CD8 (Novocastra, UK) and mast 
cell tryptase (DAKO, Denmark), and binding of the antibodies was detected as 
previously described (12).  
 
Quantitative analysis  
All coded biopsy specimens were examined by one observer, who was blinded to 
the patient and to the study day on which the biopsy was taken. 
EG-2
+
 and other inflammatory cells were quantified in the area 100 m beneath the 
epithelial basement membrane in several non-overlapping high power fields until all the 
available area was covered. The final result was expressed as the number of positive 
cells per square millimetre of submucosa. Light microscopic analysis was performed at 
a magnification of 400X for quantification of the structural parameters. Morphometric 
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measurements were performed with a light microscope (Leitz Biomed, Leica, 
Cambridge, UK) connected to a video recorder linked to a computerized image system 
(Quantimet 500 Image Processing and Analysis System, Qwin V0200B Software, 
Leica).  
 
Statistical analysis 
As the main objective of the study was to evaluate correlations between airway 
responsiveness to bradykinin and airway inflammatory markers (FeNO and EG2
+  
or 
other inflammatory cells), the needed sample size was calculated, assuming that the 
expected correlation coefficients would be around 0.7, the type I error = 0.05, the power 
= 0.80 and the t-test on the correlation coefficient ( = 0) would be two-sided. With 
these assumptions the needed sample size should be 13. 
All data are reported as median with upper and lower quartiles in parentheses unless 
otherwise stated. Wilcoxon signed rank test or paited t-test was applied to explore the 
effect of allergen on different parameters. Correlation analyses were made by Spearman 
rank correlation test (Rho). Statistical significance was accepted for a p value less than 
0.05. 
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RESULTS 
 
Quantitative immunostainings in bronchial submucosa and correlations between cells  
Satisfactory endobronchial biopsies were obtained in all subjects. The mean area of 
examined submucosa was 0.296  0.02 (mean  SEM) mm2 for all immunostainings 
performed after diluent and allergen challenge. Allergen challenge significantly 
increased the number of eosinophils (EG-2
+
 cells) and CD4
+
 cells in submucosa of the 
bronchial biopsies compared to diluent exposure (EG-2
+
 cells: 730 (456-1203) 
cells/mm
2 
vs 180 (101-268) cells/mm
2
, p = 0.004; CD4
+
 cells: 501 (444-601) cells/mm
2 
vs 269 (220-381) cells/mm
2
), p = 0.010) (Figure 1 and Figure 2). The counts of CD8
+
 
cells and mast cells in submucosa after diluent inhalation was not significantly changed 
by allergen (CD8
+
 cells: 221 (140-347) cells/mm
2 
vs  213 (152-309) cells/mm
2
, p = 
0.846; mast cells: 198 (143-257) cells/mm
2 
vs 187 (146-242) cells/mm
2
, p = 0.695) 
(Figure 2).  
The count of EG-2
+
 cells in the bronchial submucosa of atopic asthmatics were 
not correlated with CD4
+
 cells after diluent or allergen exposure (rho = 0.054 and rho = 
-0.03, respectively) (data not shown). No significant correlations were found among the 
other inflammatory cells either after diluent or after allergen exposure (data not shown). 
  
Responsiveness to bradykinin and FeNO 
As previously described (11), logPD20 bradykinin after allergen exposure 
diminished as compared to that observed after diluent inhalation (p = 0.019) (data not 
shown).  
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As previously reported (8), baseline FeNO was similar in the 2 study days before 
placebo and allergen challenges (p = NS). The values of FeNO at 48 hours after allergen 
are significantly increased from the levels of FeNO at 48 hours after diluent (p = 0.002). 
 
Correlation between inflammatory cells in bronchial submucosa, responsiveness to 
bradykinin and FeNO 
The count of EG-2
+
 cells in the bronchial submucosa of atopic asthmatics were 
negatively correlated with logPD20 bradykinin after allergen challenge (rho = -0.709, p 
= 0.027) (Figure 3A) but not after diluent exposure (rho = 0.07, p = 0.865) (data not 
shown). Conversely, the number of CD4
+
 cells in the bronchial submucosa was not 
correlated with logPD20 bradykinin both after diluent (rho = 0.018, p = 0.973) and 
allergen (rho = 0.079, p = 0.838) exposure (data not shown). 
We also found a positive strong correlation between EG-2
+
 cells and FeNO 
values in atopic asthmatics at 48 hours after both diluent (rho = 0.746, p = 0.017) (data 
not shown) and allergen (rho = 0.644, p = 0.049) challenge (Figure 3B). The number of 
CD4
+
 cells in the bronchial submucosa was not correlated with FeNO  after diluent (rho 
= -0.164, p = 0.657) and allergen (rho = -0.152, p = 0.682) exposure (data not shown). 
In addition, FeNO values negatively correlated with responsiveness to 
bradykinin only after allergen challenge (rho = -0.675, p = 0.039) (Figure 4) but not 
after diluent exposure (rho = 0.079, p = 0.838) (data not shown).  
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DISCUSSION 
At our knowledge, these data showed for the first time that FeNO could be associated 
with heightened mucosal eosinophils and AHR to bradykinin in atopic asthma at 48 
hours after allergen exposure suggesting that measurements of FeNO in atopic asthma 
during allergic exacerbation may mirror the recruitment of eosinophils in the asthmatic 
airways in conjuction with elevated AHR. 
An enhancement of eosinophils in bronchial mucosa of atopic asthmatics has been 
previously reported at 24 and 48 hours after allergen (13-15), but we did not find studies 
exploring the relationship between cellular inflammation on the airway wall of 
asthmatics and FeNO or airway responsiveness at 48 hours after allergen exposure. 
Previous studies have shown a significant relationship between airway eosinophilia, 
either in sputum and BAL of adult mild asthmatics, and FeNO levels in stable 
conditions (3, 5) or segmental NO at 24 hours after segmental allergen challenge (16). 
Here, we reported that either eosinophilic count after diluent or increased number of 
mucosal eosinophils at 48 hours after allergen exposure is clearly related to heightened 
FeNO values in atopic asthma pointing to this non-invasive method as a good and 
useful clinical marker for monitoring activation of eosinophilic inflammation either in 
stable condition (as phenotypic expression of asthma activity per se) or in the delayed 
phase of allergen-induced asthma exacerbation. 
AHR to bradykinin, an indirect stimulus, is observed only in asthmatics (11, 17), 
whilst methacholine, a direct agonist, may induce bronchoconstriction also in normal 
subjects (18),
 
indicating that airway sensitivity to bradykinin is due to functional airway 
abnormalities which are present specifically in asthma (10). In a previous study 
Roisman et al. found that AHR to bradykinin, but not to methacholine, in stable mild-to-
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moderate asthma is correlated with eosinophil count in BAL, in the epithelium, in the 
lamina propria and in total submucosa (10) demonstrating that AHR to bradykinin is 
dependent on the eosinophilic inflammatory status of the airways. The present study is 
in line with the latter observation showing that in subjects with atopic mild intermittent 
asthma after allergen exposure heightened AHR to bradykinin is related to increased 
mucosal eosinophilia suggesting a main role for eosinophils in augmented airway 
reactivity to bradykinin during allergen-induced asthma exacerbation. The lack of 
correlation between eosinophil counts in bronchial mucosa and logPD20 bradykinin after 
diluent challenge in the present study is probably due to the lower level of airway 
inflammatory activity in our “asymptomatic mild intermittent asthmatics” at baseline 
compared to the “mild-to-moderate asthmatics” (in part treated with inhaled steroids) 
showed by Rosiman et al. (10). 
In previous reports controversial correlations between FeNO and methacholine or 
histamine (direct stimuli) responsiveness in mild stable asthma have been shown (19, 
20). More recently, it has been demonstrated an association between increased FeNO 
values and the degree of AHR to the indirect stimulus mannitol (R=0,48) or, to a lesser 
extent, to the direct stimulus methacholine suggesting that the resposniveness to indirect 
stimulus might be more reflective of asthma with ongoing airway inflammation (21). In 
this study we found that after allergen challenge elevated FeNO is related to AHR to 
bradykinin (indirect stimulus) in sensitized asthmatics. We previously demonstrated that 
NO derived from the constitutive NO synthase [cNOS] isoform is involved in the 
regulation of bronchomotor tone in asthma (11), whilst NO derived from the inducible 
NO synthase [iNOS] isoform is a pro-inflammatory marker and the most important 
component of FeNO in asthma (22, 23). In the past we showed that allergen-induced 
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increase in AHR to bradykinin is dependent on the impairment of bronchoprotective 
cNOS in airway epithelium of atopic asthmatics (11). On the other hand, in the same 
larger asthma clinical trial it has been reported a dramatic increase in FeNO after 
allergen in conjuction with upregulation of iNOS in airway epithelium (8, 11). 
Thus, we may suggest that elevated FeNO, marker of asthmatic inflammatory 
activity, could indirectly reflect a potentiation of AHR to bradykinin in allergen-induced 
asthma exacerbation. 
Finally, even though we analyzed data of a limited population (10 patients), the 
study was only a little underpowered for the correlations between airway responsiveness 
to bradykinin and FeNO or EG2
+  
cells or between FeNO and EG2
+  
cells but the needed 
sample size was very close to the used one. Regarding the other correlations, these were 
clearly not present (correlation coefficient close to zero) and a reasonable increase in the 
sample size would not have changed the conclusion of no relationship. In addition, we 
were not able to increase the number of patients to reach the needed sample size since 
we performed new immunohistochemical analysis on bronchial biopsies specimens that 
had been obtained during a previous study (11).   
The present study showed, for the first time, a relationship between FeNO values, 
eosinophilic inflammation and AHR to bradykinin during allergen-induced 
exacerbation. We may point out that after allergen exposure in sensitized asthmatic 
airways eosinophilic inflammation with the subsequent release of pro-inflammatory 
mediators is able to increase inducible NO synthase-derived NO production (2), to 
directly liberate bradykinin (24)
 
 and to heighten AHR to bradykinin (11).  
In conclusion, we demonstrated that elevated FeNO seems to be directly associated 
with an increased number of eosinophils and with a potentiated airway responsiveness 
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to bradykinin in atopic asthmatics after allergen exposure. All of these data indicate that 
eosinophilic inflammation in the airway mucosa of asthmatics after allergen exposure 
could specifically be reflected by FeNO levels. Finally, the novel message of the present 
study derives also from the evidence of a link between exhaled NO and airway motor 
response to bradykinin in atopic asthmatics after allergen exposure supporting a role for 
the non-invasive monitoring of exhaled NO and airway responsiveness to bradykinin in 
asthma control. In future work, the relationships between oxidative stress (Montuschi P, 
Currò D, Ragazzoni E, Preziosi P, Ciabattoni G. Anaphylaxis increases 8-iso-
prostaglandin F2alpha release from guinea-pig lung in vitro Eur J Pharmacol. 1999 
Jan 15;365(1):59-64) and different markers of eosinophilic airway inflammation 
(Montuschi P LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled 
breath condensate for assessing lung inflammation. J Chromatogr B Analyt Technol 
Biomed Life Sci. 2009 May 1;877(13):1272-80; Montuschi P, Santonico M, Mondino C, 
Pennazza G, Mantini G, Martinelli E, Capuano R, Ciabattoni G, Paolesse R, Di Natale 
C, Barnes PJ, D'Amico A. Diagnostic performance of an electronic nose, fractional 
exhaled nitric oxide, and lung function testing in asthma.; Chest. 2010 Apr;137(4):790-
6) or AHR after allergen exposure in patients with atopic asthma should be studied. 
Whether leukotriene receptor antagonists, which reduce FENO concentrations in 
patients with atopic asthma (Montuschi P, Mondino C, Koch P, Ciabattoni G, Barnes 
PJ, Baviera G. Effects of montelukast treatment and withdrawal on fractional exhaled 
nitric oxide and lung function in children with asthma. Chest. 2007 Dec;132(6):1876-
81), also decrease airway eosinophils and AHR should be clarified. MI SEMBRA DI 
AVER CAPITO CHE IL REVISORI SI CHIAMI..............MONTUSCHI......Chissà 
come mai!!!???? 
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LEGENDS TO THE FIGURES 
 
Fig. 1. Immunoreactivity for EG-2
+
 and CD4
+
 cells in the mucosa of bronchial biopsies 
of atopic asthmatics 48 hours after diluent (panels A and C) and after allergen (panels B 
and D) challenge. Original magnification: X 400.  
 
Fig. 2. Changes in the numbers of EG-2
+
, CD4
+
 , CD8
+
  and mast cells in the mucosa of 
atopic asthmatics at 48 h after diluent [Dil] and allergen [All] challenge. Each bar 
indicates the median values in the respective group and boxes represent lower and upper 
quartiles.  
 
Fig. 3. Correlation between the numbers of EG-2
+
 cells in the mucosa of the bronchial 
biopsies and logPD20 bradykinin (Panel A) or FeNO levels (Panel B) in atopic 
asthmatics after allergen challenge. rho: Spearman rank correlation coefficient. 
 
Fig. 4. Correlation between FeNO levels and logPD20 bradykinin in atopic asthmatics 
after allergen challenge. rho: Spearman rank correlation coefficient. 
